Other languages Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Real-time Estimate Cboe BZX Other stock markets 02:02:21 2024-04-24 pm EDT			5-day change	1st Jan Change
4.06 ^USD	-5.14%		+4.08%	+101.98%

Apr. 12	Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	CI
Apr. 11	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	Apr. 12
Aquestive Therapeutics Files $250 Million Mixed Shelf	Apr. 03
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024	Apr. 01
Top Midday Decliners	Mar. 20
Sector Update: Health Care Stocks Steady Premarket Wednesday	Mar. 20
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20
Top Premarket Decliners	Mar. 20
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	Mar. 20
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	Mar. 19
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 15
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial	Mar. 14
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	Mar. 14
Aquestive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05
Aquestive Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Mar. 05
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm (epinephrine) Sublingual Film	Dec. 05
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
Aquestive Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023	Nov. 06
Aquestive Therapeutics to Start Pivotal Trial of Oral Epinephrine Product Candidate in Q4	23-09-20
Aquestive Therapeutics, Inc. Provides an Update on the Development Timeline and Pathway for Its Oral Epinephrine Product Candidate, Anaphylm	23-09-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Other languages

Filters